Evidence map›Paper›PMID 42479397›Full record

ArticleAIDS and behavior2026

Association Between Alcohol Use, CD4 Count, and Depressive Symptoms Among People with HIV with Viral Load Suppressed in Southwestern Uganda.

Alain Favina, Robin Fatch, Sowmya R Rao, Gabriel Chamie, Winnie Muyindike, Julian Adong, Nneka I Emenyonu, Adah Tumwegamire, Christine Ngabirano, Allen Kekibiina and 4 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03302299 phase4completednot on this map

URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2021Enrolled302ConditionsTuberculosis, HIV/AIDS, Alcohol AbuseArmsIsoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet
NCT03492216 nacompletednot on this map

Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2022Enrolled680ConditionsHIV/AIDS, TuberculosisArmsIncentives for negative EtG test, Incentives for positive IsoScreen test
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alain FavinaDepartment of Psychiatry, Mbarara University of Science and Technology, Mbarara, Uganda.ORCID http://orcid.org/0000-0002-2739-1713
Robin FatchDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Sowmya R RaoDepartment of Global Health, Boston University School of Public Health, Boston, MA, USA.
Gabriel ChamieDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Winnie MuyindikeDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Julian AdongDepartment of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Nneka I EmenyonuDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Adah TumwegamireGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.
Christine NgabiranoGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.
Allen KekibiinaGlobal Health Collaborative, Mbarara University of Science and Technology, Mbarara, Uganda.
Marson KaraDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Brian BeesigaInfectious Diseases Research Collaboration, Kampala, Uganda.
Adam W CarricoDepartment of Health Promotion and Disease Prevention, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, USA.
Judith A HahnDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA. judy.hahn@ucsf.edu.

Funding

The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIVP01AA029541 · NIAAA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2021 to 2025
$7.5M
Interventions to reduce alcohol use and increase adherence to TB preventive therapy among HIV/TB co-infected drinkers (DIPT 1/2)U01AA026223 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2017 to 2021
$2.8M
Training in Research Program on Alcohol Use by Persons with our at Risk for HIVK24AA022586 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAHN, JUDITH ALISSA · 2013 to 2023
$1.8M
Nation×al Institute on Alcohol Abuse and Alcoholism K24AA031211NIAAA NIH HHS K24 AA022586NIAAA NIH HHS P01 AA029541NIAAA NIH HHS U01 AA026223
6 · The paper itself

Abstract

Despite the current effective antiretroviral therapy (ART) and viral suppression, depression remains the most prevalent mental health challenge among people with HIV (PWH) in Uganda and worldwide. This study examined the relationship between CD4 cell count and depressive symptoms among PWH on ART with viral suppression, and the potential modification effect of alcohol use on this relationship. We combined baseline data from two longitudinal studies (DIPT (NCT03492216) and ADEPTT (NCT03302299)) conducted between May 2017 and August 2021 across four health facilities in Southwestern Uganda. Eligible participants were adults with suppressed HIV viral load. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression (CESD) Scale (≥ 16 considered significant). CD4 + count was measured through blood tests, while alcohol use was measured using both the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C) and the alcohol biomarker phosphatidylethanol (PEth), measured in dried blood spots. Multivariable mixed effects logistic regression models examined associations. Among 908 participants, 14.6% had depressive symptoms. The median CD4 count was 632 cells/mm³ (IQR: 467.5-825.5), and 62.1% had high or very high-risk alcohol use. Overall, no significant association was found between CD4 count and depressive symptoms (aOR: 1.04; 95% CI: 0.97-1.12; p = 0.26). Additionally, no evidence of effect modification by level of alcohol use (p = 0.10) was found. The prevalence of depressive symptoms is high among PWH with viral suppression. Healthcare providers should assess and manage depression among this population. Further studies should also explore the causes of the depressive symptoms and develop targeted interventions.

Indexed as

Alcohol useCD4 countDepressionHIV viral suppressionPeople with HIV (PLHIV)

Identifiers

PMID42479397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.